Clinical data indicates PICO™ NPWT System reduces healing time and increases patient comfort
23 May, 2012
Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces preliminary independent data showing that patients using the PICO™ Negative Pressure Wound Therapy (NPWT) System experienced reduced healing times, a higher degree of conformability, increased comfort and greater ease to use over conventional NPWT. These outcomes demonstrate how appropriately designed products such as PICO™ can improve patient wellbeing and further help reduce the human and economic cost of wounds.
Theresa Hurd, RN, MSN, MEd, will be presenting these results at the European Wound Management Association (EWMA) annual conference in Vienna on Wednesday, 23 May 2012 (12:30-13:30 in Room E1). Ms. Hurd is one of the authors of the study “Outcomes of a Portable Single Use Negative Pressure Device Trial.”
“The objective of the study was to determine what was required to introduce a new innovation in the community-based setting. Indicators we measured were healing ability, patient comfort and ease of use for the clinicians,” said Hurd. “What we found was that we were able to transition NPWT patients from acute care and keep them on NPWT longer in a cost-efficient way. We were astounded to find that the savings were in the thousands of dollars per treatment, per patient. Patient feedback on how PICO™ was able to improve their quality of life and feeling of wellbeing was resoundingly positive. They loved the size and discreetness of the system and the ease of dressing changes.1”
A total of 198 patients in a Canadian Community Care Access Centre and Acute Care Hospitals were evaluated during a six-month period for this independent clinical study. Ninety percent of patients reported that the conformability of PICO™ was good, and 81% reported that they were pleased with the system. It was also described as significantly easier to use than conventional NPWT. The trial focused on several types of wounds, including surgical wounds and venous leg ulcers.
“The innovation of PICO™ has expanded patient access to the benefits of NPWT through a single use system and demonstrates our commitment to advancing wound care technology,” said Andy Boyes, President, Europe, for the Advanced Wound Management division of Smith & Nephew. “When developing the system, as with everything we do, we sought to reduce the human and economic cost of wounds. PICO™ simplifies delivery of the proven benefits of traditional NPWT on small to medium wounds, making the treatment more affordable and cost-predictive.”
In addition to its PICO™ system and spearheading research to advance NPWT, Smith & Nephew has also recently acquired Kalypto Medical, a medical device company in the U.S., further building on its investment and commitment in NPWT.
- ends -
Magellan Communications +44 (0)77 40 948 378
Smith & Nephew +44 (0)20 7401 7646
The PICO™ NPWT System was launched in Europe in 2011 and achieved FDA approval in the U.S. in 2012. The company has ensured ethnographic market research incorporated customer feedback into the PICO™ system’s design to provide a patient-friendly experience that also addresses the needs and preferences of clinicians and payers.
PICO™ makes the therapeutic benefits of NPWT available to more patients because it is easily accessed from the shelf, easily applied and simple for the patient to manage. The PICO™ system is indicated for chronic, acute and traumatic wounds; subacute and dehisced wounds; partial-thickness burns; ulcers (such as diabetic or pressure); flaps and grafts; and closed surgical incisions. The PICO™ system is as easy to apply as a conventional wound dressing, reducing the need for the intensive training, staff time and administrative paperwork associated with traditional NPWT. The simple application technique can be viewed online via an MS Tag included on the packaging.
For more information about the PICO™ system, please visit www.mypico.com.
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith & Nephew has almost 11,000 employees and a presence in more than 90 countries. Annual sales in 2011 were nearly $4.3 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).
For more information about Smith & Nephew, please visit www.smith-nephew.com.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in integrating acquired businesses, and disruption that may result from changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.
Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
1Outcomes of a Portable Single Use Negative Pressure Wound Therapy Trial. Deroo K, Sardo A.A, Robertson-Laxton L., Hurd T, Maloney S. Presented at the Symposium of Advanced Wound Care 2012.
™ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.